EBS vs. XOMA, VNDA, MACK, VSTM, RIGL, RGLS, LXRX, OPK, INVA, and IRWD Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Merrimack Pharmaceuticals (MACK), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), Innoviva (INVA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.
XOMA (NASDAQ:XOMA ) and Emergent BioSolutions (NYSE:EBS ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
XOMA received 18 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.45% of users gave Emergent BioSolutions an outperform vote while only 65.95% of users gave XOMA an outperform vote.
In the previous week, XOMA had 1 more articles in the media than Emergent BioSolutions. MarketBeat recorded 2 mentions for XOMA and 1 mentions for Emergent BioSolutions. Emergent BioSolutions' average media sentiment score of 0.53 beat XOMA's score of -0.03 indicating that XOMA is being referred to more favorably in the media.
XOMA currently has a consensus price target of $57.00, indicating a potential upside of 123.44%. Emergent BioSolutions has a consensus price target of $5.00, indicating a potential downside of 9.91%. Given Emergent BioSolutions' stronger consensus rating and higher possible upside, equities research analysts clearly believe XOMA is more favorable than Emergent BioSolutions.
95.9% of XOMA shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 7.2% of XOMA shares are held by insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
XOMA has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Emergent BioSolutions has a net margin of -47.68% compared to Emergent BioSolutions' net margin of -705.23%. XOMA's return on equity of -18.53% beat Emergent BioSolutions' return on equity.
XOMA has higher earnings, but lower revenue than Emergent BioSolutions. XOMA is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Summary XOMA beats Emergent BioSolutions on 11 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Emergent BioSolutions Competitors List
Related Companies and Tools
